Pitolisant

Pitolisant is a first-in-class medicine that acts as an antagonist and inverse agonist at the histamine H3 receptor, a target that regulates the brain's own histamine release ^[1][3]. Structurally it is a piperidine derivative, and functionally it is grouped with the wakefulness-promoting agents used in sleep medicine.

The drug was developed by the French company Bioprojet, having earlier been studied under names such as tiprolisant and the code BF2.649. It received European marketing authorisation in March 2016 for narcolepsy with or without cataplexy in adults, and United States approval followed in August 2019 for excessive daytime sleepiness in adults with narcolepsy; it also holds orphan drug status in both regions ^[1][2].

Efficacy was established mainly through phase III trials. In the HARMONY studies pitolisant reduced excessive daytime sleepiness compared with placebo and also lowered the rate of cataplexy attacks ^[1][2][3]. In comparative work it was not shown to be non-inferior to modafinil for daytime sleepiness, yet reviews note it appeared more effective than modafinil at reducing cataplexy ^[3][4]. A frequently highlighted feature is its low potential for abuse; it is the only approved anti-narcolepsy agent in the United States that is not scheduled as a controlled substance ^[3].

Pitolisant is a prescription medicine taken as an oral tablet, and a related formulation has been marketed for daytime sleepiness linked to obstructive sleep apnoea. In line with its mechanism, the most commonly reported adverse effects are headache, insomnia, nausea and anxiety ^[2][3].

Pitolisant is a prescription drug (Wakix) with real trial backing, and it is generally well tolerated; the common gripes are headache, insomnia, nausea, and some anxiety. The big one to know is that it can prolong the QT interval, so it is avoided alongside other QT prolonging drugs and in significant heart or severe liver problems. It runs through CYP2D6 and CYP3A4, so strong inducers and inhibitors shift the dose, and it can blunt hormonal birth control, so a backup method is advised. Antihistamines oppose it and can cancel the effect. It is not a controlled substance, but this is a genuine medication best used under a doctor rather than casually.

Pitolisant is a histamine H3 antagonist, and the interaction most likely to quietly undercut it is pharmacodynamic. Centrally acting H1 antihistamines such as diphenhydramine or hydroxyzine block the downstream receptor that pitolisant reaches by raising histamine tone, so the wakefulness benefit can fade with no change in blood level at all.

Pharmacokinetically, pitolisant is cleared largely by CYP2D6. Strong CYP2D6 inhibitors including paroxetine, fluoxetine and quinidine raise its exposure roughly 2.2-fold, and CYP2D6 poor metabolizers sit at similarly elevated concentrations for genetic reasons. Strong CYP3A4 inducers such as rifampin, carbamazepine and St John's wort cut exposure by about half, which presents as loss of response.

Pitolisant also prolongs the QT interval, so pairing it with other QT-prolonging agents such as class IA or class III antiarrhythmics, or with anything that raises its own concentration, compounds arrhythmia risk. It is itself a weak CYP3A4 inducer; hormonal contraceptives are the sensitive substrate that matters most here, and reduced contraceptive efficacy is the practical concern.

Checking a whole stack? Run it through interactions + stacks.

Pitolisant emerged from the histamine H3 receptor research of Jean-Charles Schwartz at Inserm and the French company Bioprojet, developed in collaboration with the chemists Walter Schunack in Berlin and Robin Ganellin at University College London. Carrying the codename BF2.649 (and earlier called tiprolisant), it was selected as a first-in-class H3 inverse agonist after the discovery that such compounds could reverse the receptor's constitutive activity and boost brain histamine signaling. The EMA's orphan medicinal products committee granted it orphan designation in 2007, and on March 31, 2016 the European Medicines Agency approved it, marketed as Wakix, for narcolepsy with or without cataplexy in adults. The US FDA followed with approval in 2019, and a pediatric narcolepsy indication for children over six was later added.